Intercept Pharmaceuticals Receives $30,000,000 Series C Funding Round

  • Feed Type
  • Date
    8/13/2012
  • Company Name
    Intercept Pharmaceuticals
  • Mailing Address
    18 Desbrosses Street New York, NY 10013
  • Company Description
    Intercept Pharmaceuticals Inc., is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases.
  • Website
    http://www.interceptpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $30,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    This financing allows us to continue advancing our lead compound OCA in POISE, our Phase 3 PBC trial, while pursuing other therapeutic indications of interest.
  • M&A Terms
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    OrbiMed Advisors
  • Venture Investor
    Genextra S.p.A.
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.